Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've been in since December 2012....cost average of 3.01...holding strong.
Get In Now...
Before it is too late...
GLTA
Buying With Both Hands Now...
GLTA
And Will Buy In Any Weakness...
This will go to 8 or 10...
Very Soon...
GLTA
Bought today...
GLTA
Wait a second, PATH was just FDA approved for some drug- and it is trading like the opposite. :confused: definitely looking for an entry point ASAP this is very very oversold
I am watching this one also...
Weekly Chart. Hard to figure what is going on with PATH, true shake out going on for sure, now bottom of that weekly channel, and if you follow D-Mark indicators we're at selling exhaustion on the daily where we printed a confirmed bar-9 buy today, the weekly D-Mark is close but not confirmed yet (bar 7 and bar12 continuation near bar13 continuation bar. Note.. I no longer use D-Mark, but it does show good results on weekly when confirming daily imho. I still have a bunch and I'm buying again at 1.52, if it gets there. This program reports earnings call around 11-12 Nov. I'm thinking it bottoms before or just after earnings, so we're in the zone... if there is anything to "the patch" at all. Management needs a wake up call on how to treat its share holders also imho.
[URL=http://www.directupload.net][/URL]
Is this movement down all because speculation of launching alone ?
8:26AM On The Wires (WIRES) : NuPathe (PATH) announced the co has initiated dosing of patients for NP101-015, a Phase 1 study of ZECUITY (sumatriptan iontophoretic transdermal system) in adolescents with a history of migraine attacks. This open label, single-dose study will assess the safety, pharmacokinetics, and tolerability of ZECUITY in adolescent migraine patients.
Options expiry, todays move could be anticipated due large call positions. I was buying & expect PATH beginning turn from here.
NuPathe Takes 21,000 SF in Malvern
Liberty Property Trust Signs Deal with Drug Developer
NuPathe, Inc., a neuroscience drug development company, leased 21,266 square feet in the office building at 7 Great Valley Pky in Malvern, PA.
The three-story, 61,108-square-foot office building delivered in 1985, part of the Great Valley Corporate Center in the Exton / Whitelands submarket of Philadelphia.
Michele Countis and Catherine Bianco of Liberty Property Trust represented the landlord in-house. Ryan Conner of Tactix Real Estate Advisors LLC represented the tenant.
This management team sucks. Everyday I awake in the morning looking for news. Instead I get a volume of 30,000 shares and a penny movement. It's way overdue for news either good or bad.
7:01AM NuPathe announces allowance of additional U.S. patent for ZECUITY (PATH) 2.59 : Co announced that the USPTO has issued a notice of allowance for U.S. Patent application 13/407,434. This application relates to NuPathe's innovative iontophoretic patch that uses a two-stage delivery sequence to transdermally deliver sumatriptan. This, and other proprietary technology, is incorporated into NuPathe's lead product, ZECUITY (sumatriptan iontophoretic transdermal system), the first and only FDA approved patch for migraine. Given this action, co expects the patent to issue within the next few months. Once issued, the patent will provide additional protection for ZECUITY and will be the sixth patent listed in the FDA's Orange Book. NuPathe has additional U.S. patents covering ZECUITY that expire between 2027 and 2029 and patent applications pending in the U.S. and other territories.
I have read all posts on YMB for Path, and have held my shares, believing now that there will be a buyout in the multiples of our current share price. The lease is extended only through end Sept, and the 12 employees are just hanging out together, waiting for the last nuances of the deal to fall into place. Either that, or they ain't got nothin', but I am positive, have to remain positive. My other best tip for you is ATRS which has retraced to $4.31 today, and their PDUFA date is October 14th. The CCI index hasn't been this low since February, 2013 when the stock bottomed out around $3.38. I think we'll see 5.50 before the year is out, and next year is their breakout year, they should see profitability by Q4 '14. They have a huge pipeline in QST and QSM.
Any thoughts on this stock? I have been holding prior to FDA approval and I'm waiting for some good news. Just my patience is wearing thin.
Really good post Jr!... now interested in HZNP & ALXA. Still holding PATH, and probably should have bought the low at 2.38. Your post made me wonder 2 things (1) when would I actually sell PATH for a loss vs wait out the gain, (2) what is the best way to time, or is there a method, to better time these FDA approval ramp to production bio calender investments.
Re #1, imo this answer is dependent on #2, where I see (for PATH) the lack of any news as a positive, indicating buyout and/or partnering; I would be a buyer down to $2.01 on a clean reversal with no news, below I'd would probably take my lumps.
Re #2, I'm up for any suggestions. Believing in the fundamental story; for PATH I have confidence in their managers, their product and their patents. Similarly believe the story for NAVB. But like you point out believing can be a long slog.
Thanks Ringao for the signal of the long's emotional capitulation day, which fortunately neither you or others we've heard say dumped their shares. I own shares of HZNP as well, both stocks were mining new lows and on the same day both roared back to life, although PATH not as exuberantly as HZNP. It just goes to show how even well after FDA approval, there doesn't need to be a rush to own shares. Take for example ALXA, which even secured TEVA as a partner for the USA, with EMA approval in Europe and a partner there, their stock is still dragging anchor, whooshed to lows again just this week. Like you though, I know to focus beyond the pain to what I believe will be substantial profits. Good luck in your outcomes, Lord knows we've been tested here, although not like management. I can't begin to understand how they must feel as they've played their poker hand so long in their partnership or buyout talks.
Have to say, genuinely hate this stock.. which is a good contrary indicator. Not budging, seen this before.
I bought before the FDA approval. Could have sold at $4 but chose not to sell. I have high hopes long term
The trade volume signals aren't presenting well, either. I'm holding out to see how the new board proceeds. At least bankruptcy is off the table. Any news on sales partnerships in Q4 yet for Zecurity?
Good point. I was thinking with the earnings and going alone I thought there would be some chatter.
its quiet here every day, lol
Patiently waiting here too.
This thing is about to explode with partnership/buyout announcement possibly this Thursday.
7:33AM NuPathe nnounced the Company will present data on ZECUITY; Patients who had migraine-related nausea at the time of treatment were nearly twice as likely to report their headache pain (PATH) 2.84 : This was a post-hoc analysis of the randomized, parallel-group, double-blind, placebo-controlled Phase 3 clinical trial data to compare the efficacy of ZECUITY in relieving migraine headache pain and associated symptoms in patients who had nausea at baseline compared with patients who did not report nausea as a symptom at baseline. Patients who had migraine-related nausea at the time of treatment were nearly twice as likely to report their headache pain as "severe" than those without MRN at the time of treatment (31% vs. 16%).
The data showed that ZECUITY was efficacious in treating migraine headache pain and associated symptoms regardless of the presence of nausea prior to treatment. This was a post-hoc analysis of the randomized, parallel-group, double-blind, placebo-controlled Phase 3 clinical trial data to compare the incidence of treatment-emergent nausea two hours after patch activation in patients treated with ZECUITY or placebo who were nausea free at the beginning of treatment. The data showed that at two hours following patch activation, patients treated with a placebo patch (13.8%) were three times more likely to have treatment-emergent nausea as those treated with ZECUITY (4.6%). In addition, the data showed that the incidence of treatment-emergent nausea with ZECUITY was lower than placebo from one hour through 24 hours following patch activation.
titxf and gale consider it (path long )
Greater Than 5% Beneficial Owners:
Quaker BioVentures II, L.P. (3)....7,858,717....24.9%
Safeguard Scientifics, Inc. (4)....7,730,063.... 24.4%
Battelle Ventures, L.P. etal (5)....3,454,014....11.5%
GlaxoSmithKline plc etal (6)....4,183,652 .... 13.7%
Directors and Named Executive Officers
Armando Anido (8) 285,727 .... <1%
Jane H. Hollingsworth (9) 697,286 2.4%
Terri B. Sebree (10) 345,820 1.2%
Keith A. Goldan (11) 132,661 .... <1%
Michael F. Marino (12) 21,984 .... <1%
Gerald W. McLaughlin (13) 109,291 .... <1%
Michael Cola (14) 93,552 .... <1%
James A. Datin 20,620 .... <1%
William Federici (15) 28,852 .... <1%
Richard S. Kollender (16) 8,130,723 .... 25.7%
Robert P. Roche, Jr. (17) 72,484 .... <1%
Brian J. Sisko — —
Wayne P. Yetter(18) 29,815 .... <1%
* All Dir & XOs as Group (12 persons) ... 9,271,529 ... 28.6%
Includes owned, restricted , issuable and vested
FORM DEF 14A
NUPATHE INC.- PATH
Filed: April 30, 2013 (period: June 05, 2013)
8:02AM NuPathe announces allowance of additional US patent application for NP201 (PATH) 3.32 : Co announces that the USPTO has issued a notice of allowance for U.S. Patent application 11/784,526 entitled "Implants for the Treatment of Dopamine Associated States." This application relates to methods for treating dopamine associated states (such as Parkinson's disease) using a biodegradable polymer implant capable of delivering a dopamine modulating compound gradually rather than with an initial burst and maintaining an effective plasma level of the compound for a specified delivery period.
Given this action, NuPathe expects the patent to issue within the next few months. Once issued, it will provide patent protection into October 2027 for NP201, NuPathe's long-term biodegradable ropinirole implant for the treatment of Parkinson's disease and other dopamine associated disorders. NuPathe has additional licensed patent applications pending in the U.S. and other territories for NP201.
Note today from Lerink Swann
Related to patent. "We believe the notice of allowance increased the value for PATH's NP201 asset and may be attractive for a potential partner. Once issued the patent will provide protection into July 2028. We continue to expect a 4Q13 launch of Zecurity, and PATH to close a commercial US partnership deal for that product near term....Zecurity is FDA-approved with a good label and Orange Book listed patents until 2029 should be attractive features for a potential partner or acquirer. Given that PATH's current enterprise value is only ~$85MM we believe an outright acquisition of the company coudl be an alternative to a partnership.
8:03AM NuPathe announces allowance of U.S. patent application for NP201 (PATH) 3.42 : Co announced that the United States Patent and Trademark Office has issued a notice of allowance for U.S. Patent application 12/074,101 entitled "Implants for the Treatment of Dopamine Associated States." This application relates to a biodegradable polymer implant capable of delivering a dopamine modulating compound, such as ropinirole, with little or no initial burst and maintaining an effective plasma level for a specified period of time. Given this action, NuPathe expects the patent to issue within the next few months. Once issued, it will provide patent protection into July 2028 for NP201, NuPathe's long-term biodegradable ropinirole implant for the treatment of Parkinson's disease.
Thanks for posting that. I am confused but it appears the finance message boards will still be there. I still think many will flock here regardless.
Not true:
Yahoo! Message Boards shutting down
ID: SLN9007Refers to: Message Boards
Resolution
Effective April 1, 2013, Yahoo! is shutting down its Message Boards service. You'll still have the ability to post questions in Yahoo! Answers, post comments to Yahoo! articles, and use Yahoo! Groups to communicate with other Yahoo! members with similar interests.
While Message Boards are no longer available, Yahoo! Finance Message Boards will still be around to discuss important financial news and events as well as issues related to specific stocks listed in the various markets.
We regret any inconvenience this may cause.
Source:
http://help.yahoo.com/kb/index?locale=en_GB&y=PROD_ACCT&page=content&id=SLN9007
Yahoo stock message boards shutting down March 31st. I just found out today. This board will become a lot busier next month! Welcome to all new Yahoo users!
PATH could break out next week if a partnership is announced. If not it will stay in this range for a while IMO.
Buying back into PATH today....
Bought half my position at 3.18 today. I looked at the charts and with this being the second day in a row where it touched down this low I think we are seeing a bottom. will pick up the other half if she holds this tomorrow or Wed. Good luck, easy money on this play is my guess with the approval already in hand and waiting on news. Joe
Waiting for tomorrow. Want to see if she continues to drop. Might be one more day of new lows. Typical, no news and down she goes. Seems like a good play going forward though. has to be worht a buck or two on news. Good luck, joe
Started buying at 3.18
I agree! May reenter just to be in for the ride though.
My wag is folks are waiting to see if they dilute again. And yes,
what a partnership looks like. No position.
Anyone else think that PATH is a buy at these levels? Seems like it has slowly dropped on no news. I suspect it is close to a bottom and will bounce soon. If there is any whiff of news on partnership or buy out she will scream. Sleeping giant. I am out for now since she broke support line last week, but am considering coming back in about 50 cents cheaper then my last sale.
Path is oversold at 3.20. won FDA aproval on sought after drug that Merck was unable to get approved. I think this is a hidden gem. will not stay at these levels very long on news. Buy out or partnership and she is off to the races.
Followers
|
36
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
724
|
Created
|
10/07/10
|
Type
|
Free
|
Moderators |
Our first commercial product is Zecuity™ sumatriptan iontophoretic transdermal system (patch) for the acute treatment of migraine. We are seeking commercialization partners in the U.S. and worldwide.
In addition, we have a strong pipeline based on our biodegradable implant technology that allows us to deliver therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist and is being developed to provide up to two months of continuous delivery. NP202 is being developed to address patient noncompliance, a long-standing problem in the treatment of schizophrenia and bipolar disorder, by providing three months of continuous delivery of risperidone, an atypical antipsychotic. We are seeking a development partner for each of these candidates to capitalize on their commercial potential worldwide.
Beyond our current product pipeline, we intend to be a leader in the rapidly growing transdermal patch market with our active SmartRelief technology, delivering innovative solutions across a range of therapeutic areas.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |